Drug Profile
BNT 411
Alternative Names: BNT 411Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator BioNTech
- Class Antineoplastics; Small molecules
- Mechanism of Action Toll-like receptor 7 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Small cell lung cancer; Solid tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Solid-tumours in Germany (IV)
- 09 Nov 2021 Efficacy, safety and pharmacodynamics data from a phase I/II trial in Small cell lung cancer released by BioNTech
- 18 Aug 2020 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in USA, Spain, United Kingdom (IV) (NCT04101357)